- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Andrei Gonzales Discusses Struggles of Move to Value-Based Care
As the healthcare system adjusts to the transition to value-based care, providers in particular are having a hard time keeping up with all of the changes, said Andrei Gonzales, director of value-based reimbursement initiatives at McKesson Health Solutions.
As the healthcare system adjusts to the transition to value-based care, providers in particular are having a hard time keeping up with all of the changes, said Andrei Gonzales, director of value-based reimbursement initiatives at McKesson Health Solutions.
Transcript (slightly modified)
What remains the biggest hurdle facing the US in the move to value-based care?
I’d say the biggest hurdle is the transition from the current fee-for-service structure, to a value-based reimbursement structure. The study that we did shows that providers are struggling, and they are lagging payers in their progression towards value-based reimbursement.
And you know, providers have a very busy job right now just to take care of their patients, and the transition requires a lot of work in terms of building care coordination capabilities, in terms of building data integration so that all the different stakeholders in the continuum of care really understand what’s happening for their patients in these value-based models and understand where opportunities for improvement are, and to be able to make those changes to really see the improvements that they’re looking for. So that transition is going to be a very heavy lift; it has been and it’s going to continue to be until we reach more of a steady state and gone through this transition phase.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
